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Abstract
Understanding the requirements for protection against pneumococcal carriage and pneumonia will greatly benefit efforts in
controlling these diseases. Several proteins and polysaccharide capsule have recently been implicated in the virulence of
and protective immunity against Streptococcus pneumonia. Pneumococcal surface protein A (PspA) is highly conserved
among S. pneumonia strains, inhibits complement activation, binds lactoferrin, elicits protective systemic immunity against
pneumococcal infection, and is necessary for full pneumococcal virulence. Identification of PspA peptides that optimally
bind human leukocyte antigen (HLA) would greatly contribute to global vaccine efforts, but this is hindered by the
multitude of HLA polymorphisms. Here, we have used an experimental data set of 54 PspA peptides and in silico methods to
predict peptide binding to HLA and murine major histocompatibility complex (MHC) class II. We also characterized spleen-
and cervical lymph node (CLN)-derived helper T lymphocyte (HTL) cytokine responses to these peptides after S. pneumonia
strain EF3030-challenge in mice. Individual, yet overlapping peptides, 15 amino acids in length revealed residues 199 to 246
of PspA (PspA199–246) consistently caused the greatest IFN-c, IL-2, IL-5 and proliferation as well as moderate IL-10 and IL-4
responses by ex vivo stimulated splenic and CLN CD4
+ T cells isolated from S. pneumonia strain EF3030-challeged F1
(B66BALB/c) mice. IEDB, RANKPEP, SVMHC, MHCPred, and SYFPEITHI in silico analysis tools revealed peptides in PspA199–246
also interact with a broad range of HLA-DR, -DQ, and -DP allelles. These data suggest that predicted MHC class II-peptide
binding affinities do not always correlate with T helper (Th) cytokine or proliferative responses to PspA peptides, but when
used together with in vivo validation can be a useful tool to choose candidate pneumococcal HTL epitopes.
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Introduction
Pneumococcal pneumonia is the most common cause of
childhood deaths in the developing world and among the top
ten causes of death in aged populations worldwide; recently,
antibiotic-resistant S. pneumonia strains have emerged [1,2,3,4].
Hence, vaccines against these strains are greatly needed. This
study characterizes the HTL epitopes of a candidate pneumococ-
cal vaccine antigen, PspA, which is a highly conserved, cell wall-
associated surface protein that plays a major role in pneumococcal
virulence by binding human lactoferrin and interferes with com-
plement deposition on the bacterial surface [5]. During the course
of invasive disease, antibodies against PspA peak during the
convalescent phase, but CD4
+ T cell help is required for optimal
protective immune responses to PspA [6,7].
A central event in the adaptive immune response to invasive
microorganisms is the specific recognition of processed antigens
bound to the peptide-binding region of MHC class II molecules on
the surface of antigen-presenting cells. These peptide antigens are
subsequently detected by the T cell receptor (TCR) of CD4
+ T
cells, which proliferate, secrete cytokines, and differentiate into
antigen-specific Th effector cells. To induce protective immunity,
HTL epitopes contained in synthetic peptide vaccines must: (i)
match those naturally presented to the immune system during
infection, (ii) be recognized by the majority of the human popu-
lation, and (iii) induce an appropriate effector immune response to
eliminate the pathogen of interest. Single epitope-based vaccines
may, however, have drawbacks. For example, the mono-specificity
of the induced immune response might miss the emergence of
sequence mutants that would potentially escape the vaccine’s
protective effect [8]. It is also unlikely that T cells from genetically
distinct populations would recognize, and respond to a single
peptide epitope.
These obstacles are secondary to the wide-ranging polymor-
phisms of HLA molecules that present antigenic peptides to T
cells. Indeed, a unique set of epitopes from a given protein antigen
will be presented to T cells of an individual bearing hundreds of
unique HLA molecules. Additionally, some HLA molecules may
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9432not be able to bind to any of the peptides derived from a given
protein [9,10]. The major challenge of peptide-based vaccines is
the identification of one or more epitope(s) that bind to many HLA
alleles and cover close to 100% of the genetically diverse human
population [11]. Thus, the identification of peptides that bind to
multiple HLA types, the so-called ‘‘promiscuous’’ or ‘‘universal’’
epitope(s), could lead to effective coverage of the human
population using peptide-based vaccine.
Until recently, the search for immunodominant peptides relied
on the direct testing of overlapping peptides or peptide libraries.
Fortunately, the identification of MHC binding motifs allowed for
the prediction of potential T cell epitopes [12,13]. To identify the
immunodominant epitopes of PspA, we used in silico MHC affinity
measurement methods using both affinity data from the Immune
Epitope Database and Analysis Resource (IEDB) [14], eluted
peptide data from the SYFPEITHI [12] database as well as
RANKPEP [15], SVMHC [16], and MHCPred tools [17,18],
which predicted the PspA peptides that bind HLA-DR, -DQ, and
-DP alleles. To correlate these predictions with in vivo immuno-
genicity, PspA-specific HTL proliferation and cytokine responses
were measured and correlated with predicted peptide-MHC
binding affinities. A novel human isolate of capsular group 19
pneumococci, which was passed in mice to yield S. pneumonia strain
EF3030, which has a greater propensity to cause nasal or
pulmonary infections than sepsis when given intranasally, was
used to accomplish this objective [19]. Further, F1 (B66Balb/c)
mice have reduced susceptibility to S. pneumonia strain EF3030 and
express functional I-A
b, I-A
d, I-E
b, and I-E
d. After these mice were
nasally challenged with S. pneumonia strain EF3030, CLN- and
spleen-derived CD4
+ T cells were isolated and ex vivo stimulated
with PspA peptides. Together, these in silico and in vivo methods
revealed immunodominant PspA HTL epitopes that might serve
as vaccine antigens.
Results
Peptide Selection, Binding Analysis, and Overview of
PspA Predicted Secondary Structure
The aligned PspA amino acid sequence using 24 unrelated S.
pneumonia strains, was previously shown to contain helical and
charged immunogenic domains (i.e., Regions A, A*, B, and C)
[20]. As reported previously, the secretion signal peptide for PspA
extends into the first 50 amino acids and has .50% amino acid
identity among strains. Region A encodes the first 100 amino acids
(,300 nucleotides) of PspA, beginning with the first amino acid of
the mature protein. PspA is less conserved over the second half of
Region A, where sequences begin to diverge and fall into groups.
The amino terminal end of Region A* is hypervariable, but the C-
terminal end of Region A* and much of Region B are more
conserved among strains. Region C is proline-rich.
We created individual, yet overlapping peptides, that were 15
amino acids in length (Table 1). The entire sequence of PspA was
used to predict the protein structure as well as b turn (t) using
PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/)[21] and COUDES
(http://bioserv.rpbs.jussieu.fr/Coudes/index.html) [22] methods.
Coiled–coiled (C) as well as helical (H) structures were noted
throughout PspA (Figure 1). There were no b turns or potential
asparagine (N) endopeptidase sites in Regions A or A*.The majority
of Region B is coiled with small helix (PspA242–246) and strand
(PspA286–293) domains. In contrast, Region C displays an array of
complex secondary structures as well as numerous potential N
endopeptidase sites. The latter sites are typically found in bacterial
cell wall-associated domains and known to enhance antigen-
processing for MHC presentation [23].
Next, the PspA peptide dataset was was used to determine
MHC II binding affinities (Table 2). These data span a total of 16
human and 4 mouse MHC class II types. IEDB, MHCPred,
RANKPEP, SVMHC and SYFPEITHI MHC class II epitope
databases scanned the entire sequence of PspA. In brief, PspA
peptides were compared with archived peptide datasets of
previously measured peptide-MHC class II affinities. Peptides
were classified into binders (IC50,500 nM) and non-binders
(IC50$500 nM) based on in silico-derived binding affinities. This
analysis revealed that nearly all PspA peptides could potentially
bind a variety of mouse and human MHC class II molecules.
Finally, the amino acid sequence comprising PspA peptides 19
to 22 (or PspA199–246) was aligned with sequences from nearly
100 clinically relevant family 1 S. pneumonia strains (Table 3).
PspA199–246 is highly conserved among S. pneumonia strains and
contains the C-terminal end of Region A* and the beginning of
Region B [20].
PspA Peptide-Specific Systemic and Mucosal CD4
+ T Cell
Proliferation Responses
To better determine whether predicted PspA peptide-MHC
class II binding affinities corresponded with HTL proliferation,
PspA peptide-specific CD4
+ T cell responses were characterized
28 days after S. pneumoniae strain EF3030 or mock (naı ¨ve)
challenge. PspA peptide-specific proliferative responses by naı ¨ve
CD4
+ T cells were relatively low (Figure 2). However, spleen- or
CLN-derived CD4
+ T cell from S. pneumonia strain EF3030-
challenged mice showed selective yet significant proliferation
indexes to PspA peptides. Spleen-derived HTLs from S. pneumonia
strain EF3030-challenged mice significantly proliferated in re-
sponse to PspA peptides 21, 22, and 23 than compared to naı ¨ve
controls. CLN CD4
+ T cell PspA peptide-specific proliferation
responses were moderately higher than similar cells isolated from
the spleen of S. pneumonia strain EF3030-challenged mice, with
comparatively higher responses to PspA peptides 21 and 23.
PspA Peptide-Specific T Helper Cytokine Profiles
In general, pneumococcal infection resulted in significantly
higher HTL cytokine secretion by ex vivo PspA peptide-stimulated
CD4
+ T cells from the spleen as well as CLNs of S. pneumonia strain
EF3030-challenged mice, than compared to naı ¨ve mice (Figures 3
and 4). In contrast to proliferation responses, spleen-derived CD4
+
T cells from S. pneumonia strain EF3030-challenged mice secreted
higher levels of IFN-c and IL-2 after PspA peptide ex vivo
stimulation than did similar cells from CLNs. HTLs from CLNs of
pneumococcal-challenged mice, significantly responded to PspA
peptides 20 and 21. CD4
+ T cells isolated from the spleen and
CLNs also significantly secreted Th2 cytokines after ex vivo
stimulation of PspA peptides, than compared to naı ¨ve mice.
Similar to proliferation responses, CLN CD4
+ T cells from S.
pneumonia strain EF3030-challenged mice significantly secreted IL-
10 following PspA peptide restimulation, with comparatively
higher responses to PspA peptides 19, 20, and 21. Splenic HTLs
selectively secreted significant levels of IL-10 in response to PspA
peptides 13, 19, and 21 than compared to naı ¨ve mice (Figure 5).
While cells from naı ¨ve mice did not significantly respond to PspA
peptides, CD4
+ T lymphocytes from S. pneumonia strain EF3030-
challenged mice also significantly secreted IL-4 and IL-5 after
PspA peptide ex vivo stimulation (Figures 6 and 7). In particular,
there were comparatively higher responses to PspA peptides 19,
20, and 21 by splenic HTLs. Similar CLN Th2 cells secreted IL-4
in response to peptides 19 and 20 whereas heightened IL-5
secretion was noted in response to peptides 19 to 22 as well as 29
and 35, than compared to naive mice.
PspA HTL Epitopes
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+ T cells from S. pneumonia strain EF3030-
challenged mice consistently mounted significant yet select
proliferation and IL-10 responses (CLN..spleen), IFN-c, IL-2
and IL-4 secretion (spleen..CLN) and IL-5 expression
(spleen#CLN) largely in response to PspA peptides 19, 20, 21,
and 22. Moreover, PspA peptides 21 and 22 mounted compar-
atively high proliferation responses, 20 and 21 induced consistently
high IFN-c and IL-2 responses, and 19, 20, and 21 caused IL-10,
IL-4 and IL-5 responses by HTLs isolated from Pneumococci-
exposed mice.
Predicted PspA Peptide-MHC Class II Alleles Binding
Affinities and Correlation with Proliferation and Cytokine
Secretion Responses
PspA peptides 19, 20, 21, and 22 mounted significant HTL
responses, and displayed strong predictive binding affinities to
n u m e r o u sH L A - D R ,- D Q ,a n d- D Pa sw e l la sI - A
b and I-E
d
haplotypes. This is best illustrated by viewing a 3-dimensional plot of
the proliferation index as wellas IFN-c,I L - 1 0 ,I L - 2 ,I L - 4 ,a n d / o rI L -
5 responses compared with MHC allele binding affinities (Figures 8
and 9). PspA peptide-specific T cell proliferation and IFN-c,I L - 1 0 ,
IL-2, IL-4 and IL-5 secretion by CLN and splenic CD4
+ Tc e l l sf r o m
S. pneumoniastrain EF3030-challenged mice was higher than the naı ¨ve
group. In general, CLN HTLs from mice previously challenged with
S. pneumonia strain EF3030) secreted high levels of IFN-c,I L - 2 ,I L - 4 ,
IL-5 and IL-10 as well as enhanced proliferation in response to PspA
peptides (19, 20.21, 22) stimulation.
PspA peptides 19, 20, 21, and 22 were predicted to bind I-A
b/I-
A
d, I-A
b/I-E
b, I-A
b and I-A
b/I-A
d, respectively, with
IC50,500 nM. From these, PspA peptide 20 was predicted to
have marginal binding affinities to I-A
b and I-E
b with IC50=485
and 493 nM, respectively. This also corresponded with relatively
high IL-10 responsiveness. Spleen-derived CD4
+ T cells secreted
significant amounts of IFN-c, IL-2, IL-4 and IL-5 as well as
proliferated in response to PspA peptides 19, 20, 21, and 22 (i.e.,
PspA199–246) stimulation from mice previously challenged with S.
pneumonia strain EF3030. Peptide 20 or 23 stimulation of splenic
HTLs resulted in comparatively high secretion of IL-10. Similar to
PspA peptide 20, peptide 23 was predicted to have moderate I-A
b
and I-E
b binding affinity i.e., IC50=452 and 412 nM, respectively.
Peptides that induced spleen-derived CD4
+ T cells to secrete high
levels of Th1 (IFN-c/IL-2) and Th2 (IL-4/IL-5) cytokines also
correlated with relatively high MHC binding affinities. It is
important to note that several PspA peptides predicted to tightly
bind I-A and/or I-E alleles did not always correspond with
elevated cytokine secretion (e.g., peptides 6, 18, 30, and 53).
Table 1. Overlapping PspA peptides and antigenic region description.
Peptide Antigenic epitope region Peptide Antigenic epitope region
01-MNKKKMILTSLASVA Leader 28-TIAAKKAELEKTEAD Region B
02-ASVAILGAGFVASQP Leader 29-TEADLKKAVNEPEKP Region B
03-ASQPTVVRAEESPVA Leader/Region A 30-PEKPAPAPETPAPEA Region B/C
04-SPVASQSKAEKDYDA Region A 31-APEAPAEQPKPAPAP Region C
05-DYDAAKKDAKNAKKA Region A 32-APAPQPAPAPKPEKP Region C
06-AKKAVEDAQKALDDA Region A 33-PEKPAEQPKPEKTDD Region C
07-LDDAKAAQKKYDEDQ Region A 34-KTDDQQAEEDYARRS Region C
08-DEDQKKTEEKAALEK Region A 35-ARRSEEEYNRLTQQQ Region C
09-ALEKAASEEMDKAVA Region A 36-TQQQPPKAEKPAPAP Region C
10-KAVAAVQQAYLAYQQ Region A 37-APAPKTGWKQENGMW Region C
11-AYQQATDKAAKDAAD Region A 38-NGMWYFYNTDGSMAT Region C
12-DAADKMIDEAKKREE Region A* 39-SMATGWLQNNGSWYY Region C
13-KREEEAKTKFNTVRA Region A* 40-SWYYLNSNGAMATGW Region C
14-TVRAMVVPEPEQLAE Region A* 41-ATGWLQYNGSWYYLN Region C
15-QLAETKKKSEEAKQK Region A* 42-YYLNANGAMATGWAK Region C
16-AKQKAPELTKKLEEA Region A* 43-GWAKVNGSWYYLNAN Region C
17-LEEAKAKLEEAEKKA Region A* 44-LNANGAMATGWLQYN Region C
18-EKKATEAKQKVDAEE Region A* 45-LQYNGSWYYLNANGA Region C
19-DAEEVAPQAKIAELE Region A* 46-ANGAMATGWAKVNGS Region C
20-AELENQVHRLEQELK Region A* 47-VNGSWYYLNANGAMA Region C
21-QELKEIDESESEDYA Region A*/B 48-GAMATGWLQYNGSWY Region C
22-EDYAKEGFRAPLQSK Region B 49-GSWYYLNANGAMATG Region C
23-LQSKLDAKKAKLSKL Region B 50-MATGWAKVNGSWYYL Region C
24-LSKLEELSDKIDELD Region B 51-WYYLNANGAMATGWV Region C
25-DELDAEIAKLEDQLK Region B 52-TGWVKDGDTWYYLEA Region C
26-DQLKAAEENNNVEDY Region B 53-YLEASGAMKASQWFK Region C
27-VEDYFKEGLEKTIAA Region B 54-QWFKVSDKWYYVNGL Region C
Individual, yet overlapping, Streptococcus pneumonia strain R6 PspA peptides, 15 amino acids in length were used in ex vivo and in silico assays. The antigenic epitope
regions based on homologous alignment of PspA amino acid sequences from other strains were previously described as leader, A, A*, B, and C regions [20].
doi:10.1371/journal.pone.0009432.t001
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PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9432Figure 1. Modular PspA amino acid sequence showing regions of predicted immunogenicity and secondary structure. Major domains
of PspA are indicated. The aligned amino acid sequence shows the previously defined PspA windows A, A*, B and C. The PspA amino acid (AA)
sequence was used to predict helical (H), coiled (C), a strand (E), b turns (t), and asparagine endopeptidase sites (N).
doi:10.1371/journal.pone.0009432.g001
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PspA Peptide
Number IC50 in silico prediction (nM)
I-A
b I-A
d I-E
b I-E
d HLA-DRB, -DP, -DQ Alleles with IC50,500 nM predicted peptide-binding affinity
01 312 177 – – 1*0101, 1*0301, 1*0401, 1*0404, 1*0405, 1*0701, 1*0802, 1*0901, 1*1101, 1*1302, 4*0101, 5*0101
02 316 81 – 372 1*0101, 1*0401, 1*0404, 1*0701, 1*1501,DP4, DPw4, DQ1, DQ5
03 171 21 358 – 1*0101, 1*0301, 1*0401, 1*0901, 1*0701, 5*0101
04 71 302 – – 1*0101, 1*0404, 1*0701, DP4, DP9
0 5 ––––1 * 0 101, 1*0404, 1*0701, 1*0802, 5*0101, DQ5
06 167 56 – – 1*0101, 1*0404, 1*0701, DP9, DQ1, DQ5
0 7 3 3 8 –––1 * 0 101, 1*0404, 1*0701, DQ8
08 118 17 – – 1*0101, 1*0404, 1*0701
09 219 57 499 – 1*0101, 1*0404, 1*0701, DP4, DPw4,
10 193 12 – 337 1*0101, 1*0404, 1*0701, 4*0101, DQ1, DQ2, DQ5, DQ7
11 223 215 – – 1*0101, 1*0401,1*0701, 1*0901, 3*0101, DQ8
12 380 488 – – 1*0101, 1*0301, 1*0701, 5*0101, DQ2
13 241 – 348 – 1*0101, 1*0401,1*0701, 1*0802, 5*0101, DP9, DPw4, DQ7, DQ8
14 210 34 – – 1*0101, 1*0401, 1*0701, 1*0405, 5*0101
15 354 46 – – 1*0101, 1*0401,1*0701, 1*0901, 5*0101, DP9 , DQ1, DQ2
16 182 99 – 344 1*0101, 1*0401,1*0701, DP9 , DQ7
1 7 4 9 –––1 * 0 101, 1*0401,1*0701, DP9, DQ2
18 208 12 – 307 1*0101, 1*0401,1*0701, 1*0901, DQ8
19 205 104 – – 1*0101, 1*0401,1*0701, DQ2
20 485 – 493 – 1*0101, 1*0301,1*0401,1*0701, DP4, DP9, DPw4, DQ1
2 1 1 8 0 –––1 * 0 1 0 1
22 121 42 – – 1*0101, 1*0401,1*0701,DP4, DP9, DQ1, DQ5
23 452 – 412 – 1*0101, 1*0401, 1*0405, 1*0701, 1*0802, 1*0901, 5*0101,DP4, DP9
2 4 3 7 4 –––1 * 0 101, 1*0401,1*0701,
25 365 461 – – 1*0101, 1*0401,1*0701, DP9, DQ2
26 462 6 – – 1*0101, 1*0401,1*0405,1*0701, 5*0101, DQ2
27 249 112 – – 1*0101,1*0401, 1*0405, 1*0701, 1*0901, 5*0101,DP4, DP9, DQ5
28 124 190 – – 1*0101, 1*0401,1*0701, DP9, DQ7, DQ8
29 97 10 411 – 1*0101, 1*0401,1*0701, 1*0901, 5*0101, DQ5
30 99 125 – – 1*0101, 1*0401,1*0701, DQ2
31 173 57 – – 1*0101, 1*0401,1*0701, DQ2
32 350 15 – – 1*0101, 1*0401,1*0701, DQ2
3 3 2 3 9 –––1 * 0 101, 1*0401,1*0701,
34 349 28 – – 1*0101, 1*0401,1*0701, DQ1
35 457 155 210 – 1*0101, 1*0401,1*0701, DPw4
36 211 65 – 479 1*0101, 1*0401,1*0701, DQ2
37 369 20 – 381 1*0101, 1*0401,1*0701,
38 140 105 – 378 1*0101, 1*0401, 1*0405, 1*0701, 1*1101, DQ1, DQ5, DQ7, DQ8
39 204 121 – 285 1*0401, 1*0405, 1*0701, 1*1302, 1*1501
40 348 76 381 – 1*0101, 1*0401, 1*0404, 1*0405, 1*0701, 1*0901, 1*1101, 1*1302, 1*1501, 5*0101,DP4, DPw4
41 264 60 268 – 1*0101,1*0401, 1*0404, 1*0405, 1*0701, 1*1302, 1*1501
42 256 175 – 357 1*0101, 1*0401, 1*0404, 1*0405, 1*0701, 1*0901, 1*1101, 1*1302, DQ8
43 329 21 – – 1*0101, 1*0401,1*0405, 1*0701, 1*1501, 3*0101, 5*0101
44 274 7 – – 1*0101, 1*0401, 1*0405, 1*0701, 1*1101, 1*1302, DQ7
45 485 60 – 476 1*0101, 1*0401, 1*0404, 1*0405, 1*0901, 1*1101, 3*0101, 5*0101
46 – 44 – – 1*0101, 1*0401, 1*0405, 1*0701, 1*1101
47 255 21 – – 1*0101, 1*0401, 1*0404, 1*0405, 1*0701, 1*0901, 1*1101, 1*1302, 3*0101, 5*0101
48 264 47 – – 1*0101,1*0401, 1*0404, 1*0405, 1*0701, 1*1302, 1*1501
49 255 120 – – 1*0101, 1*0401, 1*0404, 1*0405, 1*0701, 1*0901, 1*1101, 1*1302, 5*0101
PspA HTL Epitopes
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The immune system is remarkably robust in responding to a
multitude of foreign antigens. T cells are crucial for generating an
efficient immune response following recognition of foreign antigen
in the context of MHC. The polymorphism of MHC genes leads
to differences in immune responsiveness. While peptide vaccines
potentially circumvent the problem of using whole antigen or
attenuated pathogens as vaccines, this approach is impeded by the
exhaustive MHC repertoire [24]. Hence, the identification of
optimal or common HTL epitopes is imperative in mounting a
protective immune response. To this end, MHC a chains have
limited variability compared to MHC b chains suggesting that the
binding affinity of MHC b chains dictates antigenic specificity
[25,26]. This restricts the utility of peptides as vaccines. The
discovery of ‘‘promiscuous’’ or ‘‘universal’’ peptides that can bind
multiple HLA (b chain) allele would solve many of these problems.
While HLA-transgenic mice have been used to map HTL epitopes
[27], the limited number of HLA transgenic mice are not
representative of all populations. Hence, the current study is the
first of many to map clinically relevant HTL pneumococcal
epitopes. We have utilized in silico methods for predicting class II-
restricted peptides and evaluated immunogenicity by ex vivo
peptide-restimulation.
Protein secondary structure consists of regular elements such as
a-helices and b-sheets, and irregular elements such as b-bulges,
random coils, and tight turns. Tight turns are generally classified
as d-, c-, b-, a-, and p-turns according to the number of residues
involved [28]. b-turns have important biological tasks [29]. We
predicted b-turns in PspA using a new and highly accurate
secondary structure prediction software, PSIPRED, which incor-
porates two feed forward neural networks that perform an analyses
on PSI-BLAST position-specific-iterated- BLAST peptide se-
quence [30]. b-turns were abundant in PspA Region C, which
did not have immunodominant HTL epitopes. While b-sheet
structures were not detected, analysis revealed PspA has a-helical
secondary structure content and is predominantly a coiled-coil
structure. These structural properties correlate with PspA function
and anti-complement activity [31]. In general, PspA peptides with
continuous helix or strand predicted secondary structures were not
considered immunodominant; instead, PspA peptides 19, 20, 21,
and 22 (or PspA199–246) were estimated to predominantely have a
coiled secondary structure.
In addition to protein secondary structure, proteases and MHC
class II co-mingle in the antigen-processing compartment and
compete for peptides that satisfy requirements for protease or
MHC recognition, respectively. Indeed, several proteases are
implicated in processing antigen and the MHC class II-bound
invariant chain [32,33,34]. The proteolytic separation of MHC
class II-bound epitopes was found to be a rate-limiting step in the
presentation of T cell epitopes [35]. The level and activity of N
endopeptidases can directly control the proteolysis and presenta-
tion of T cell epitopes [36]. In contrast to other proteases, N
endopeptidase is required for both antigen and invariant chain (Ii)
processing [37,38,39,40]. Hence, N endopeptidase can have both
positive and negative effects on the outcome of antigen processing
[23,41,42]. Future studies will be required to verify whether the
candidate HTL peptides are able to induce protective immunity
against to pneumococcal infection.
PspA is highly immunogenic and is considered a promising
vaccine candidate for combating pneumococcal infection
[43,44,45]. In our model, S. pneumonia strain EF3030 promoted
substantial PspA peptide-specific HTL responses. We show that
PspA199–246 (i.e., PspA peptides 19, 20, 21, and 22) is highly
immunogenic and likely encompasses HLA class-binding epitopes
to support pneumococcal immunity. Further, PspA 199–246 is
highly conserved among 100 different family 1 S. pneumonia strains
(Table 3). In confirmation, Region B lies within PspA199–246 and
was found to be important in eliciting protective pneumococcal
immunity [46]. Taken together, our findings support the rationale
for additional studies to explore the utility of PspA199–246-based
vaccines.
S. pneumonia has co-evolved with man and no doubt has
numerous immune evasion mechanisms to avoid detection by T
cells. From the pathogen’s perspective, it would be critical to
maintain PspA function, while reducing detection of a T cell
immuno-dominant epitope (i.e., peptide 21). PspA peptide 21
restimulation of pneumococcal-infected mice induced significant
cytokine production and proliferation, yet was predicted to be
poorly recognized by mouse and human MHC class II alleles. In
contrast, other immunodominant regions exist within peptides 38
to 41 and might be protective since they invoked CD4
+ T cell
proliferation as well as T helper cytokine responses. However,
these peptides reside in Region C, which has several potential, N
endopeptidase sites along with b turn secondary structures that
would optimally expose these sites for cleavage. In particular,
peptide 40 has a highly conserved N endopeptidase site (i.e., NxN)
that lies in the middle of a pronounced b turn secondary structure
(ttttt). While this intact peptide would potentially bind several
MHC class II alleles, it is also likely that it would be cleaved before
or after MHC-binding by N endopeptidases.
The Th1-associated cytokine, IL-2 promotes T cell prolifera-
tion. Our data show PspA199–246 peptides mounted comparatively
high IL-2 and proliferation HTL recall responses in mice
PspA Peptide
Number IC50 in silico prediction (nM)
I-A
b I-A
d I-E
b I-E
d HLA-DRB, -DP, -DQ Alleles with IC50,500 nM predicted peptide-binding affinity
5 0 3 2 9 –––1 * 0 101, , 1*0401, 1*0405, 1*0701, 1*1501
51 255 45 – – 1*0101, 1*0401, 1*0404, 1*0405, 1*0701, 1*0901, 1*1101, 1*1302, 5*0101,DP4, DQ5
52 392 204 – – 1*0101, 1*0301,1*0401, 1*1501,1*0701
53 80 27 – – 1*0101, 1*0401, 1*0701, 1*0901, 5*0101,DP4, DPw4, DQ5
54 387 234 – 170 1*0101, 1*0401, 1*0701, 1*1501, 3*0101, DQ8
*Dashes (–) represent the predicted affinity of peptides that poorly (i.e., IC50.500 nM) bind mouse I-A
b, I-E
b, I-A
d, or I-E
d alleles. Similarly, absent HLA alleles are those
that poorly (i.e., IC50.500 nM) bind the corresponding peptide.
doi:10.1371/journal.pone.0009432.t002
Table 2. Cont.
PspA HTL Epitopes
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PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9432Figure 2. Proliferation responses of PspA peptide-specific systemic and mucosal CD4
+ T cells during pneumococcal carriage. Spleen
and cervical lymph node (CLN) lymphocytes were isolated from F1 (B66Balb/c) mice, 28 days after intranasal challenge with Streptococcus pneumonia
strain EF3030 (&) and naı ¨ve (%). CD4
+ T cells were incubated with 1 mM of PspA peptide (15 amino acid peptides that overlapped every 11 residues)
plus mitomycin C-treated naı ¨ve syngeneic feeder cells, for 3 days, at a ratio of 5:1610
6 cells. Proliferation was measured by BrdU incorporation, which
was measured by ELISA. The data presented are the mean OD450. Experimental groups consisted of 10 mice. The results were expressed as the mean
6 the standard error mean (SEM) of the response from 3 replicate determinations of three independent experiments.
doi:10.1371/journal.pone.0009432.g002
Figure 3. PspA peptide-specific IFN-c secretion by CD4
+ T cell following pneumococcal challenge. Groups of 10 F1 (B66Balb/c) mice were
intranasally challenged with 10
7 CFUs of S. pneumonia strain EF3030 in a 15 ml volume of Ringer’s solution. Spleen and cervical lymph node (CLN) lymphocytes
were isolated from mice, 28 days after intranasal challenge with Streptococcus pneumonia strain EF3030 (&) and naı ¨ve (%). CD4
+ T cells were incubated with
1 mM of PspApeptide(15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naı ¨ve syngeneic feeder cells, for 3 days, at a ratio of
5:1610
6 cells. The results were expressed as the mean 6 the standard error mean (SEM) of IFN-c supernatant levels from 3 replicate determinations of three
independent experiments. IFN-c production of cultured supernatants was determined by Luminex capable of detecting .2 pg/ml of IFN-c.
doi:10.1371/journal.pone.0009432.g003
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Th1 cytokine, IFN-c, is required for protective pneumococcal
immunity [47]. CD4
+ T cells from S. pneumonia strain EF3030-
challenged mice secreted significant amounts of IFN-c following ex
vivo PspA peptide re-stimulation. IFN-c blockade accelerated the
death of animals during pneumococcal infection [48], whereas
treatment of mice with IFN-c enhanced the survival of mice [49].
However, confounding studies suggest that too much IFN-c and
too little IL-10 can inhibit pneumococcal clearance during S.
pneumonia infection that is secondary to influenza virus infection
[50].
IL-10 has been suggested to be both deleterious and important
for pneumococcal immunity. On one hand, administration of anti-
IL-10 antibody was shown to enhance pneumococcal immunity
[51], while others showed this Th2-associated cytokine is critical
for MARCO-1 expression and subsequent pneumococcal clear-
ance [50]. We show that PspA199–246 stimulates pneumococcal
strain EF3030-primed CD4
+ T cells to secrete IL-10. Interestingly,
HTLs from CLN mounted IL-10 responses to more peptides, than
similar cells isolated from the spleen. Perhaps this contributes to
establishing pneumococcal carriage by supporting selective
pneumococcal clearance by CLN..spleen antigen-presenting
cells after stimulation with CD4
+ T cell-derived IL-10, whereas
IFN-c-secreting HTLs might support spleen..CLN macrophag-
es activation and/or internalization of S. pneumonia.
In the absence of IL-10, a marked increase in pro-inflammatory
cytokines is induced during pneumococcal infection [52]. To this
end, IL-10 plays an indispensable role in mucous cell metaplasia
and hyperplasia. IL-10 attenuates the proinflammatory cytokine
response and its absence hampers effective clearance of the
infection, and reduces survival of pneumococcal infection [53]. We
have shown that CCL5 inhibition resulted in lower IFN-c-
secreting CD4
+ T cells and significantly more PspA-specific IL-10-
producing CD4
+ T cells, which corresponded with the transition
from pneumococcal carriage to lethal pneumonia [45,54]. Thus,
the precise contribution of IL-10 in pneumococcal immunity
remains uncertain, but the preponderance of the evidence suggests
excessive IL-10 responses play a deleterious role in pneumococcal
immunity, but moderate levels of this cytokine are required for
optimal adaptive (humoral) immune responses to S. pneumonia and
reduced mucosal hyperplasia.
An effective intranasal conjugate pneumococcal vaccine using
interleukin-12 (IL-12) as a mucosal adjuvant induced protection
and increased expression of lung and splenic IFN-c and IL-10
mRNAs and protected mice from lethal challenge [55]. Thus,
interplay and requirement of the HTL-derived IFN-c and IL-10 in
pneumococcal carriage and pneumonia will require further study.
In addition, the adjuvants or cytokines, e.g., IL-12, required by
antigen presenting cells to promote IFN-c and IL-10 secreting,
PspA-specific T cells will be addressed in the future.
Some studies suggest that Th2 cytokines do not support optimal
pneumococcal immunity. Mice primed to mount Th2 cell responses
followed by pneumococcal infection showed an increase in the
numberofPneumococciandanincreaseinsinusinflammationthan
compared to naive or Th1 -primed groups [56]. IL-4 plays a central
role in directing the development of the Th2 phenotype and IL-4
responses in lung have been associated with an increased risk to
pneumococcal infection [57]. While IL-4 does not stimulate T cell
proliferation, it induces the growth of lymphoblasts [58]. IL-5 was
originally defined as a Th2 cell-derived cytokine that triggers B cell
Figure 4. PspA peptide-specific IL-2 secretion by CD4
+ T cell following pneumococcal challenge. Groups of 10 F1 (B66Balb/c) mice were
intranasally challenged with 10
7CFUs of S. pneumonia strain EF3030 in a 15 ml volume of Ringer’s solution. Spleen and Cervical lymph node (CLN)
lymphocytes were isolated from mice, 28 days after intranasal challenge with Streptococcus pneumoniae strain EF3030 (&) and naı ¨ve (%). CD4
+ T cells
were incubated with 1 mM of PspA peptide (15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naı ¨ve syngeneic
feeder cells, for 3 days, at a ratio of 5:1610
6 cells. The results were expressed as the mean 6 the standard error mean (SEM) of IL-2 supernatant levels
from 3 replicate determinations of three independent experiments. IL-2 production of cultured supernatants was determined by Luminex capable of
detecting .2 pg/ml of IL-2.
doi:10.1371/journal.pone.0009432.g004
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specific HTLs from S. pneumonia strain EF3030-challenged mice
secreted significant amounts of IL-4 (spleen..CLN) and IL-5
(spleen#CLN) largely in response to PspA peptides 19, 20, 21, and
22. However, the uncertain role of IL-4 and IL-5 in pneumococcal
cellular immunity makes correlations of these cytokines with
protective immunity difficult.
The role of Th17 cells in pneumococcal immunity has not been
extensively studied. However, recent reports suggest that IL-17A
supports antibody responses to pneumococcal capsular polysac-
charides [60]. Mice lacking the IL-17A receptor or mice with
neutrophil depletion are more susceptible to pneumococci [61].
Additional studies on the role of HTL-derived IL-17 would greatly
contribute to the field and will be required to understand how
secretion of this cytokine correlates with pneumococcal immunity.
While the precise role of peptide MHC class II interactions that
determine protective pneumococcal immunity are not known, this
study addresses important questions that are relevant to MHC
polymorphisms and antigen responsiveness. A number of studies
have definitively proven a cause and effect relationship between
human MHC genes and resistance to infection [62,63] as well as
autoimmune diseases [64]. I-A, which is highly homologous to
HLA-DQ [65], typically restricts antigen-specific CD4
+ T cells in
mice, whereas I-E (homologous to HLA-DR) [66,67,68] has been
reported to control non-responsiveness through antigen-specific
suppressor cells [69]. Further studies will be required to determine
whether I-E or I-A as well as DQ or DR molecules might be
involved in pneumococcal antigen non-responsiveness or cytokine
secretion in mouse or man, respectively. To this end, many of the
PspA peptides were predicted to bind I-A, while relatively few
were predicted to bind I-E. These studies support the use of in silico
and in vivo methods to validate T cell responsiveness to PspA
peptide-based vaccines.
Materials and Methods
Animals
Female F1 (B66Balb/c) mice, aged 8 to 12 weeks, contain
MHC class II haplotype and corresponding TCR diversity that
approaches those seen in man [70,71] and were purchased from
Jackson Laboratories. All mice were housed in horizontal laminar
flow cabinets free of microbial pathogens. Routine antibody
screening for a large panel of pathogens and routine histological
analysis of organs and tissues were performed to insure that mice
were pathogen free.
S. pneumonia Strain EF3030 Growth and Challenge
S. pneumonia capsular strain EF3030 was among the human
isolates of capsular group 19 that were previously examined and
found to be relatively non-invasive in mice [72]. Pneumococci
were grown in Todd Hewitt broth and stored frozen in aliquots at
280uC, in 20% glycerol, in sterile lactated Ringer’s solution
(Ringer’s) (Abbott Labs, North Chicago, IL) [73,74]. To establish
nasal carriage, Pneumococci were introduced into groups of mice
(8 to 12 week old) by nasal administration. The animals were
anesthetized with ketamine (100 mg/ml) and xylazine (20 mg/ml),
mixed at a 4:1 (vol/vol) ratio. The anesthesia mixture was injected
intramuscularly into the right hamstring muscle at a dose of
100 mg of ketamine per kg of body weight. After anesthesia was
established, the mice were inoculated with approximately 10
7
Figure 5. PspA peptide-specific IL-10 secretion by CD4
+ T cell following pneumococcal challenge. Groups of 10 F1 (B66Balb/c) mice
were intranasally challenged with 10
7CFUs of S. pneumonia strain EF3030 in a 15 ml volume of Ringer’s solution. Spleen and Cervical lymph node
(CLN) lymphocytes were isolated from mice, 28 days after intranasal challenge with Streptococcus pneumonia strain EF3030 (&) and naı ¨ve (%). CD4
+ T
cells were incubated with 1 mM of PspA peptide (15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naı ¨ve
syngeneic feeder cells, for 3 days, at a ratio of 5:1610
6 cells. The results were expressed as the mean 6 the standard error mean (SEM) of IL-10
supernatant levels from 3 replicate determinations of three independent experiments. IL-10 production of cultured supernatants was determined by
Luminex capable of detecting .2 pg/ml of IL-10.
doi:10.1371/journal.pone.0009432.g005
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+ T cell following pneumococcal challenge. G r o u p so f1 0F 1( B 6 6Balb/c) mice were
intranasally challenged with 10
7CFUs of S. pneumonia strain EF3030 in a 15 ml volume of Ringer’s solution. Spleen and Cervical lymph node (CLN) lymphocytes
were isolated from mice, 28 days after intranasal challenge with Streptococcus pneumonia strain EF3030 (&) and naı ¨ve (%). CD4
+ T cells were incubated with
1 mM of PspApeptide(15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naı ¨ve syngeneic feeder cells, for 3 days, at a ratio of
5:1610
6 cells. The results were expressed as the mean 6 the standard error mean (SEM) of IL-4 supernatant levels from 3 replicate determinations of three
independent experiments. IL-4 production of cultured supernatants was determined by Luminex capable of detecting .2p g / m lo fI L - 4 .
doi:10.1371/journal.pone.0009432.g006
Figure 7. PspA peptide-specific IL-5 secretion by CD4
+ T cell following pneumococcal challenge. G r o u p so f1 0F 1( B 6 6Balb/c) mice were
intranasally challenged with 10
7CFUs of S. pneumonia strain EF3030 in a 15 ml volume of Ringer’s solution. Spleen and Cervical lymph node (CLN) lymphocytes
were isolated from mice, 28 days after intranasal challenge with Streptococcus pneumonia strain EF3030 (&) and naı ¨ve (%). CD4
+ T cells were incubated with
1 mM of PspApeptide(15 amino acid peptides that overlapped every 11 residues) plus mitomycin C-treated naı ¨ve syngeneic feeder cells, for 3 days, at a ratio of
5:1610
6 cells. The results were expressed as the mean 6 the standard error mean (SEM) of IL-5 supernatant levels from 3 replicate determinations of three
independent experiments. IL-5 production of cultured supernatants was determined by Luminex capable of detecting .2p g / m lo fI L - 5 .
doi:10.1371/journal.pone.0009432.g007
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of Ringer’s solution using a 25-gauge ball-tipped gavage needle
[75]. Experimental groups consisted of 10 mice and studies were
repeated 3 times. The guidelines proposed by the committee for
the Care of Laboratory Animal Resources Commission of Life
Sciences - National Research Council were followed to minimize
animal pain and distress. All procedures involving mice were
approved by the Morehouse School of Medicine Committees
(IACUC).
Pneumococcal Antigens
54 overlapping peptides, spanning the entire length of S.
pneumonia strain D39/R6 PspA protein sequence (NCBI Accession
# NP_357715), starting with the first 15 residues at the N-
terminus, was synthesized by the multipin synthesis method by
Chiron Mimotopes Peptide Systems. Peptides overlapped by four
amino acids (Table 1) and were acetylated at the N- terminus and
ended with a COOH-terminal. Purity of these peptides was
approximately 95%. The peptides were dissolved in a mixture (v/
v) of 75% dimethyl sulfoxide and 25% water, to a concentration of
70 mM, divided into small aliquots and stored frozen at 280uC.
Tissue Collection and Cell Isolation
Mice were sacrificed by CO2 inhalation to collect spleen and
CLNs for single cell isolation of lymphocytes 28 days following S.
pneumonia strain EF3030 challenge. Individual single cell suspen-
sions of spleen and CLNs were collected and prepared by
aseptically removing tissues and passage through a sterile wire
screen. Unpooled CD4
+ T cells were further separated by
OctoMACS
TM (Miltenyi Biotec) using negative selection. Re-
maining (non-CD4
+) cells, were used as accessory feeder cells for
antigen peptide-specific stimulation assays after mitomycin C
(Sigma-Aldrich) treatment.
Cytokine Quantitation by Luminex
TM Analysis
Purified CD4
+ T cells and mitomycin C-treated feeder cells
were cultured at a density of 5610
6 and 10
6 cells per ml,
respectively, in complete medium containing 1 mM of each PspA
peptide at 37uCi n5 %C O 2. For the assessment of cytokine
production, 100 mL of culture supernatants from 96-well flat
bottom plates (Corning Glass Works) were harvested 3 days after
ex vivo PspA peptide stimulation to determine the levels of IL-10
and IFN-c secreted by CD4
+ T cells. phorbol-12-myristate-13-
acetate (PMA) 1 mg/ml was used as a positive control , ovalbumin
(1 mg/ml) and medium only is used as negative control to reduce
the background reading. Supernatant cytokine levels were
determined by the Beadlyte
TM mouse multi-cytokine detection
(Bio-Rad). Briefly, filter bottom ELISA plates were rinsed with
100 mL of Bio-plex assay buffer and liquid was removed using a
Millipore
TM Multiscreen Separation Vacuum Manifold System set
at 5 mm Hg. Analyte beads in assay buffer were added to the wells
followed by 50 mL of serum or standard solution. The plates were
Figure 8. 3D plot of Th1/Th2 cytokine secretion relative to proliferation or I-A/I-E predicted peptide-binding by cervical lymph
node-derived CD4
+ T cells. The panels summarize IFN-c, IL-10, IL-2, IL-4, IL-5 and proliferation responses of PspA peptide-specific CD4
+ T cells
isolated from cervical lymph nodes of F1 (B66Balb/c) mice, 28 days after S. pneumonia strain EF3030- challenge and predicted I-A or I-E binding
affinities. Y-axis and X-axis indicate the concentration (ng/ml) of IFN-c and IL-10, IL-2, IL-4, IL-5 respectively, secreted by PspA peptide-stimulated
CD4
+ T cells. The Z- axis represents the predicted I-A or I-E binding affinities (Kd). PspA peptides 19, 20, 21 and 22 appear as white circles, while
remaining peptides are open circles.
doi:10.1371/journal.pone.0009432.g008
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shaking (at setting #3) using a Lab-Line
TM Instrument Titer Plate
Shaker. The filter bottom plates were washed, as before, and
centrifuged at 3006g for 30 seconds. Subsequently, 50 mL of anti-
mouse IL-10 or IFN-c antibody-biotin reporter solution was added
in each well, after which the plates were incubated with continuous
shaking for 30 min followed by centrifugation and washing. Next,
50 mL streptavidin-phycoerythrin (PE) solution was added, and the
plates were incubated with continuous shaking for 10 min at RT.
125 mL of Bio-plex assay buffer was added, and Beadlyte
TM
readings were measured using a Luminex
TM System and
calculated using Bio-plex
TM software (Bio-Rad). The cytokine
Beadlyte
TM assays were capable of detecting .5 pg/mL for each
analyte.
Cell Proliferation
Lymphocyte proliferation was measured by a 5-Bromo-29-
deoxy uridine (BrdU) absorption and detection (Roche Diagnos-
tics). In brief, purified CD4
+ T cells were cultured at a density of
5610
6 cells/mL, with 10
6 mitomycin C-treated feeder cells/mL in
complete medium containing 1 mM of PspA peptide at 37uCi n
5% CO2. After 2 days of ex vivo antigen stimulation, cells were
transferred to polystyrene 96 well plates (Corning Glass Work).
10 mL of BrdU labeling solution (10 mM final concentration per
well) were added and incubated for 18 hours at 37uC with 5%
CO2. The cells were then fixed and incubated with 100 mLo f
nuclease in each well for 30 minute at 37uC. The cells were
washed with complete media and incubated with BrdU-POD
solution for 30 minute at 37uC. BrdU incorporation was
developed with an 2,29–azino-bis 3- ethylbenzthiazoline-6-sulfonic
acid (ABTS) solution and optical density (OD) was read at
450 nm. The proliferation index (PI) was calculated as follows.
Antigen-specific CD4
+ T cell proliferation was obtained by
measuring 5-Bromo-29-deoxy uridine (BrdU) incorporation, ac-
cording to manufacturer’s instructions (Roche Diagnostics). BrdU
absorption or optical density at 450 nm (OD450) was detected
using a scanning multi-well SpectraMax 250 spectrophotometer
(Molecular Devices). PI=OD450 in peptide stimulated cell/OD450
in un-stimulated cells6100. The results were expressed as mean 6
the standard error mean (SEM) of the response of 3 replicate
determinations from three independent experiments. Statistical
significance was assessed by student’s t test.
MHC Class II Epitope Prediction Using External Tools
IEDB (http://www.immuneepitope.org/), SYFPEITHI (http://
www.syfpeithi.de/), SVMHC (http://www.bs.informatik.unituebingen.
de/SVMHC/), RANKPEP (http://bio.dfci.harvard.edu/RANKPEP/),
and MHCPred (http://www.jenner.ac.uk/MHCPred) external
software(s) were used to predict peptide binding affinities to mouse
I-A and I-E as well as HLA-DR, -DP and -DQ. In brief, for average
relative binding (ARB) evaluation, 10-fold cross validation results
stored at IEDB were used to estimate performance. Because the
Figure 9. 3D plot of Th1/Th2 cytokine secretion relative to proliferation or I-A/I-E predicted peptide-binding by spleen- derived
CD4
+ T cells. The panels summarize IFN-c, IL-10, IL-2, IL-4, IL-5 and proliferation responses of PspA peptide-specific CD4
+ T cells isolated from spleen
of F1 (B66Balb/c) mice, 28 days after S. pneumonia strain EF3030-challenge and predicted I-A or I-E binding affinities. Y-axis and X-axis indicate the
concentration (ng/ml) of IFN-c and IL-10, IL-2, IL-4,IL-5 respectively, secreted by PspA peptide-stimulated CD4
+ T cells. The Z-axis represents the
predicted I-A or I-E binding affinities (Kd). PspA peptides 19, 20, 21 and 22 appear as white circles, while remaining peptides are open circles.
doi:10.1371/journal.pone.0009432.g009
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exact size, derivation of MHC class II ARB matrices followed an
iterative procedure. For the first iterative step, a matrix was
generated from a set of nine-residue core sequences randomly
obtained from each peptide sequence in the training set. For
subsequent cycles, nine-residue core sequences were used to
generate a matrix. The overall binding affinity of a peptide was
predicted using the highest scoring nine-residue core sequence. For
the SYFPEITHI prediction, we patched each testing peptide with
three glycine residues at both ends before evaluation for prediction.
This was recommended by the creators of SYFPEITHI method to
ensure that all potential binders were correctly presented to the
prediction algorithm. For all other methods, the original tested
peptides were submitted directly for prediction. Peptide sequences
were sent to web servers one at a time and predictions were
extracted from the server’s response. To assign a single prediction
for peptides longer than nine amino acids in the context of tools
predicting the affinity of 9 core-binding regions, we took the highest
affinity prediction of all possible 9-mers within the longer peptide as
the prediction result. For each MHC class II molecule whose
binding can be predicted by three or more algorithms, the top three
methods were selected that gave the best performance. For each
method, peptides were tested and ranked by their scores with higher
ranks for better binders. For each tested peptide, three ranks from
different methods were taken and the median rank was taken
as the consensus score. Peptides were classified into binders
(IC50,500 nM) and nonbinders (IC50$500 nM), as practical
cutoffs.
Statistics
Data are expressed as the mean 6 SEM and compared using a
two-tailed student’s t-test or an unpaired Mann Whitney U test.
The results were analyzed using Microsoft Excel for Macintosh
computers and were considered statistically significant if p values
were less than 0.01. When cytokine or antibody levels were below
the detection limit (BD), they were recorded as one-half the lower
detection limit for statistical analysis.
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